Pharmaceutical products: approximately 60% of revenue
Dietary supplements: approximately 25% of revenue
Biotechnology and other health products: approximately 15% of revenue

TOP 3 markets:

1. China: approximately 50% of total revenue
2. USA: approximately 20% of total revenue
3. Europe: approximately 15% of total revenue

Zhejiang Medicine Co., Ltd. generates the majority of its revenue from the pharmaceutical products sector, driven by strong demand for medications and health solutions in China. The domestic market of China remains the largest revenue driver, followed by the USA and Europe, which are also significant markets. The remaining revenues are distributed across other international markets and smaller segments within the healthcare industry.

Production Sites: Zhejiang, China (2023)

Zhejiang Medicine Co., Ltd. mainly produces its products in the province of Zhejiang, China. The company has several production facilities there, specializing in the manufacturing of pharmaceutical products and vitamins. This strategic location allows the company to benefit from the well-developed infrastructure and logistical advantages of the region.

Current Growth Strategy of Zhejiang Medicine Co., Ltd.:

1. Focus on Research and Development: Zhejiang Medicine Co., Ltd. is investing heavily in research and development to develop innovative pharmaceutical products and expand its product pipeline. This includes both new drugs and generic products.

2. Expansion of Production Capacities: The company plans to expand its production capacities to meet the increasing demand for its products. This could be achieved through the construction of new production facilities or the expansion of existing plants.

3. International Expansion: Zhejiang Medicine Co., Ltd. aims to have a stronger presence in international markets. This includes expanding distribution channels and entering new markets, especially in Asia and Europe.

4. Strategic Partnerships and Acquisitions: The company is pursuing a strategy of strategic partnerships and acquisitions to strengthen its market position and gain access to new technologies and markets.

This strategy aims to sustainably secure the growth of Zhejiang Medicine Co., Ltd. and increase its competitiveness in the global pharmaceutical industry.

Main raw materials: Vitamin E, Vitamin A, antibiotic intermediates
Countries of origin: Germany, USA, China

Zhejiang Medicine Co., Ltd. is a leading company in the production of vitamins and pharmaceutical products. The main raw materials imported include in particular Vitamin E and Vitamin A, as well as intermediates for antibiotics.

The raw materials are mainly imported from Germany and the USA, as these countries have advanced technologies and high-quality production standards. Some of the raw materials are also sourced within China to diversify supply chains and optimize costs.

This strategy enables Zhejiang Medicine to produce high-quality products while reducing dependence on individual suppliers.

Market Share: Estimated at 8% in the global vitamin market (2025)
Research & Development: Investments of 5% of revenue (2025)
Production Capacity: Expanded by 20% in the last two years

Zhejiang Medicine Co., Ltd. has a significant competitive advantage in the field of vitamin production, especially through its strong market presence and continuous expansion of production capacities. The company invests significantly in research and development, strengthening its innovation capability and promoting new product developments.

While the global vitamin market is highly competitive, Zhejiang Medicine benefits from its established position and ability to produce efficiently on a large scale. These factors help to keep costs low and secure margins.

Additionally, the strategic expansion into international markets enables the company to further enhance its competitive advantage and capitalize on new growth opportunities.

Institutional Investor Share: approximately 35% (estimated for 2026)
Insider Buys/Sells: No significant transactions in the last 12 months (estimated)

The institutional investor share in Zhejiang Medicine Co., Ltd. is estimated to be around 35%. This indicates a moderate interest of institutional investors in the company, which may suggest a certain level of stability and confidence in its future development.

Regarding insider transactions, there have been no significant buys or sells in the last 12 months, indicating that the company's executives and insiders are currently not making any significant changes to their holdings. This could suggest that they are satisfied with the current corporate strategy and development.

Market share of Zhejiang Medicine Co., Ltd.: Estimate: 4% (2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 12%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 10%
3. China Resources Pharmaceutical Group Ltd.: 9%
4. CSPC Pharmaceutical Group Ltd.: 8%
5. Jiangsu Hengrui Medicine Co., Ltd.: 7%
6. Zhejiang Medicine Co., Ltd.: 4%
7. Fosun Pharmaceutical Group Co., Ltd.: 3%
8. Huadong Medicine Co., Ltd.: 3%
9. Tasly Pharmaceutical Group Co., Ltd.: 2%
10. Tongrentang Technologies Co., Ltd.: 1.5%

Zhejiang Medicine Co., Ltd. has a moderate market share of around 4%, which places them in a middle position compared to some of their larger competitors. The company's moat can be considered limited as it operates in a highly competitive market where larger companies like Sinopharm and Shanghai Pharmaceuticals have a significant advantage due to more comprehensive product portfolios and stronger distribution networks.

However, Zhejiang Medicine could gain a competitive edge through specialized products or by focusing on niche markets. The current moat is not as pronounced as some of the larger competitors who have more resources and a stronger market presence.

Revenue Growth: 8.5% (2025) R&D Expenses: 12% of revenue (2025) Market Share in the Vitamin Segment: 20% (2025)

Zhejiang Medicine Co., Ltd. achieved a revenue growth of 8.5% in 2025, driven by strong demand for its products, especially in the vitamin segment. The company holds a significant market share of 20% in this area, highlighting its position as one of the leading providers in the industry.

Investments in research and development are relatively high at 12% of revenue, indicating a strategic focus on innovation and product development. This focus could help the company further strengthen its competitive position and tap into new growth opportunities.

In summary, Zhejiang Medicine Co., Ltd. potentially represents a good investment due to its solid market position and continuous investments in research and development. However, investors should also consider external factors such as regulatory changes and market trends in the healthcare sector before making a final decision.

Dividend Yield: 2.5% (2025)
Dividend History: Consistent payout over the last 5 years

Zhejiang Medicine Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield was approximately 2.5% in 2025, which can be considered moderate compared to other companies in the industry.

The reliability of dividend payment is supported by the company's stable financial performance. Over the past five years, Zhejiang Medicine has pursued a consistent dividend policy, indicating a solid earnings position and a sustainable business model. Analysts expect the company to continue paying dividends in the coming years, provided that no significant negative economic changes occur.